In:
Cancer Medicine, Wiley, Vol. 7, No. 5 ( 2018-05), p. 1794-1801
Abstract:
Prostate‐specific antigen nadir ( nPSA ) after radiotherapy for localized prostate cancer has been investigated as a predictor. However, nPSA usually requires several years, limiting its clinical utility. We investigated the significance of nPSA within 12 months ( nPSA 12) after low‐dose‐rate prostate brachytherapy ( LDR ‐ PB ) or external beam radiotherapy ( EBRT ) on treatment outcomes. Between 2006 and 2014, 663 patients with prostate cancer were treated with LDR ‐ PB or EBRT at two institutions. Four hundred and seventy‐four men received LDR ‐ PB and 189 men received EBRT , without androgen deprivation therapy. The Kaplan–Meier method was used for biochemical failure ( BF )‐free survival ( BFFS ) and distant metastasis ( DM )‐free survival ( DMFS ) analyses, and multivariable Cox regression analysis was performed. The median follow‐up was 61.3 months. The median nPSA 12 in the LDR ‐ PB and EBRT cohorts was 0.7 and 1.0 ng/ mL , respectively. The 7‐year BFFS and DMFS rates in LDR ‐ PB patients with nPSA 12 ≤ 0.7 ng/ mL were 99.1% and 99.5%, respectively; when nPSA 12 was 〉 0.7 ng/ mL , they were 90.2% and 94.8%, respectively. In EBRT patients with nPSA 12 ≤ 1.0 ng/ mL , BFFS and DMFS rates were 85.4% and 98.5%, respectively; when nPSA 12 was 〉 1.0 ng/ mL , they were 67.1% and 87.2%, respectively. nPSA 12 was an independent predictor of BF and DM in both cohorts ( LDR ‐ PB , P = 0.004 and 0.020, respectively; EBRT , P = 0.005 and 0.041, respectively). The nPSA 12 after LDR ‐ PB or EBRT is significantly associated with treatment outcomes of prostate cancer. Higher nPSA 12 may identify patients at high risk of relapse who might benefit from salvage treatment.
Type of Medium:
Online Resource
ISSN:
2045-7634
,
2045-7634
DOI:
10.1002/cam4.2018.7.issue-5
Language:
English
Publisher:
Wiley
Publication Date:
2018
detail.hit.zdb_id:
2659751-2
Permalink